These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12625028)

  • 1. Corticotropin-releasing hormone modulators and depression.
    Holsboer F
    Curr Opin Investig Drugs; 2003 Jan; 4(1):46-50. PubMed ID: 12625028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists.
    Holsboer F; Ising M
    Eur J Pharmacol; 2008 Apr; 583(2-3):350-7. PubMed ID: 18272149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRH signaling. Molecular specificity for drug targeting in the CNS.
    Refojo D; Holsboer F
    Ann N Y Acad Sci; 2009 Oct; 1179():106-19. PubMed ID: 19906235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRH-sub-1 receptor antagonists for the treatment of depression and anxiety.
    Ising M; Holsboer F
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):519-28. PubMed ID: 18179304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential uses of corticotropin-releasing hormone antagonists.
    Zoumakis E; Rice KC; Gold PW; Chrousos GP
    Ann N Y Acad Sci; 2006 Nov; 1083():239-51. PubMed ID: 17148743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Getting closer to affective disorders: the role of CRH receptor systems.
    Müller MB; Wurst W
    Trends Mol Med; 2004 Aug; 10(8):409-15. PubMed ID: 15310462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The stress system in the human brain in depression and neurodegeneration.
    Swaab DF; Bao AM; Lucassen PJ
    Ageing Res Rev; 2005 May; 4(2):141-94. PubMed ID: 15996533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases.
    Gilligan PJ; Li YW
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):487-97. PubMed ID: 15338958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The neuroendocrinology of stress and the pathophysiology and therapy of depression and anxiety].
    Ströhle A
    Nervenarzt; 2003 Mar; 74(3):279-91; quiz 292. PubMed ID: 12627245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
    Nielsen DM
    Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does amygdaloid corticotropin-releasing hormone (CRH) mediate anxiety-like behaviors? Dissociation of anxiogenic effects and CRH release.
    Merali Z; Khan S; Michaud DS; Shippy SA; Anisman H
    Eur J Neurosci; 2004 Jul; 20(1):229-39. PubMed ID: 15245495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of electroconvulsive therapy on the CRH-ACTH-cortisol system in melancholic depression: preliminary findings.
    Kling MA; Geracioti TD; Licinio J; Michelson D; Oldfield EH; Gold PW
    Psychopharmacol Bull; 1994; 30(3):489-94. PubMed ID: 7878187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stress responsive neurohormones in depression and anxiety.
    Ströhle A; Holsboer F
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S207-14. PubMed ID: 14677081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New directions in the development of antidepressants: the interface of neurobiology and psychiatry.
    Nemeroff CB
    Hum Psychopharmacol; 2002 Jun; 17 Suppl 1():S13-6. PubMed ID: 12404664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety.
    Keck ME
    Amino Acids; 2006 Oct; 31(3):241-50. PubMed ID: 16733617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonpeptide corticotropin-releasing hormone receptor type 1 antagonists and their applications in psychosomatic disorders.
    Contoreggi C; Rice KC; Chrousos G
    Neuroendocrinology; 2004; 80(2):111-23. PubMed ID: 15523186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticotropin releasing hormone receptor alterations elicited by acute and chronic unpredictable stressor challenges in stressor-susceptible and resilient strains of mice.
    Anisman H; Prakash P; Merali Z; Poulter MO
    Behav Brain Res; 2007 Aug; 181(2):180-90. PubMed ID: 17517441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.
    Zobel AW; Nickel T; Künzel HE; Ackl N; Sonntag A; Ising M; Holsboer F
    J Psychiatr Res; 2000; 34(3):171-81. PubMed ID: 10867111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corticotropin-releasing hormone and urocortin: redundant or distinctive functions?
    Gysling K; Forray MI; Haeger P; Daza C; Rojas R
    Brain Res Brain Res Rev; 2004 Dec; 47(1-3):116-25. PubMed ID: 15572167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.